Background: Severe acute uncomplicated pyelonephritis is an infection of the kidneys that usually have an ascending route and occur in presumably healthy urinary tract. The most common pathogen involved is E. coli. The Infectious Diseases Society of America (IDSA) has issued an updated guideline in 2010 suggesting IV quinolones to be considered in the initial empiric antimicrobial therapy giving known resistance of less than 10%. However, E. coli resistance to quinolones has been increasing, the recent data of E. coli, causing pyelonephritis, resistance is not known in the Midwest. Local hospital antibiogram for two years showed up to 22% resistance to ciprofloxacin among E. coli isolates. Methods: We conduct a retrospective non-concurrent cohort study in one teaching hospital in the Midwest, females who were admitted with severe acute uncomplicated pyelonephritis in a three years period were included. Patients with urinary tract obstruction, pregnancy, immuno-suppression, males, and indwelling Foley's catheters were excluded. Data collected include causative pathogens and resistance to antibiotics were collected. Percentages, frequencies, and measures of central tendency and dispersion were calculated to describe the study sample Results: 73 patients were included in the final analysis. E. coli was the most common isolated pathogen (81%), followed by other enteric gram negative. E. coli resistance to ciprofloxacin was 13.5%, 37% to trimethoprim-sulfamethoxazole, and 5% to ceftriaxone. Conclusion: Ciprofloxacin should be avoided initially in treating severe acute uncomplicated pyelonephritis until culture results and sensitivity is available.
Introduction
Acute pyelonephritis is a severe infection of the kidney, usually have an ascending route of infection, that carries an annual incidence of 15 -17 cases per 10,000 population among females [1] . It is classified into complicated and uncomplicated pyelonephritis, where complicated urinary tract infection (UTI) occurs in patients with abnormal urinary tract. UTI and pyelonephritis are considered uncomplicated when it occurs in non-pregnant females and presumed healthy urinary tract [2] [3] . E. coli is the most common cause of uncomplicated pyelonephritis accounting for almost 80%, followed by other enteric gram negative bacteria [1] [3] .
The Infectious Diseases Society of America (IDSA) has issued in 2010 a clinical practice guideline for the treatment of uncomplicated cystitis and pyelonephritis in women. It recommends the use of intravenous antimicrobial, such as fluoroquinolones; an aminoglycoside; an extended-spectrum cephalosporin or extended-spectrum penicillin; or carbapenem [2] . They also suggest considering the local E. coli antimicrobial resistance when selecting the initial intravenous antimicrobial, resistance prevalence threshold above which the fluoroquinolones is not recommended is 10% [3] . Rates of quinolones resistance among E. coli have shown an upward trend [4] . Consequently, IDSA has suggested continuing monitoring local E. coli resistance and evaluating its rate over time to sustain optimum empiric therapy [2] .
According to our knowledge, local data for E. coli resistance is missing in the Midwest, it has been reported that United State medical centers have higher rates of resistance than Canadian centers. This study was performed at a community hospital in the Midwest, the hospital's microbiology antibiogram for 2016 has shown 20% in vitro ciprofloxacin resistance among E. coli isolates (in 2015 it was 22%). Ceftriaxone resistance was only 5%; this antibiogram reported all E. coli isolates from all sources (blood, urine, skin, etc.) and doesn't differentiate between clinical infection or colonization.
The aim of this study is to follow the E. coli resistance trend in the Midwest following the IDSA recommendation.
Methods
Setting: A 443-bed public teaching hospital located in the Midwest. 
Results
A total of 72 patients met the criteria for analysis; selected sociodemographic characteristics, laboratory findings, outcomes, and co-morbidities are summarized in Table 1 . Mean age was 35.2 years, 22% of the patients are diabetic, and these patients have controlled diabetes mellitus and has no genitourinary complications. Patients with neurogenic bladder as a complication from diabetes mellitus were excluded.
Causative bacteria are summarized in Table 2 . Most common organism was Escherichia coli, followed by Klebsiella pneumonia. This is consistent with the known causative agents for urinary tract infections in general.
Resistance pattern of E. coli is summarized in Table 3 , 5% of the isolates were ESBL positive. Ceftriaxone was chose as the first empirical antibiotics in 58% of the cases while ciprofloxacin in 30.5%. Among E. coli isolates, 13.5% were resistant to Ciprofloxacin.
There was no in-hospital deaths or development of CD colitis.
Discussion
Acute uncomplicated pyelonephritis that is severe enough requiring admission E. coli is the most common causative pathogen in uncomplicated pyelonephritis as well as UTI (75% -90%) [1] [6] . Our study showed that E. coli is responsible for 81% of the cases. Quinolones and Ciprofloxacin are widely used in treating uncomplicated pyelonephritis and considered to be highly effective for inpatient and outpatient management [7] . In our study, 30 % of patients received Ciprofloxacin as the initial antibiotics. Some E. coli strains can develop resistance to ciprofloxacin through either changes in the targeted protein or decreased penetration, and that is acquired through chromosomal mutation [8] [9] . Recent studies has suggested an increasing trend of Cipro resistance among E. coli isolates [10] . IDSA and some recent review articles has suggested a threshold of 10% Cipro resistance above which Quinolones should not be used empirically before the sensitivity results [2] [3]. Our study found 13.5% resistance among ciprofloxacin in E. coli isolates in female patients admitted with severe acute uncomplicated pyelonephritis, this increasing resistance maybe due to increasing usage of quinolones in general treating the simple cystitis. It was also noted that E. coli has high resistance to trimethoprim-sulfamethoxazole (37%). This is higher than the previously reported resistance range from previous studies (up to 22%) [10] .
This study suggests using other antibiotics than ciprofloxacin and trimethoprimsulfamethoxazole that are known to be effective empirically until culture results are back in treating severe uncomplicated pyelonephritis inpatient. Weather these results should be used in treating mild to moderate cases of pyelonephritis is uncertain, additional studies are required to determine valid resistance patterns.
Limitations
Our study included only patients with severe pyelonephritis requiring inpatient treatment. The reported E. coli resistance could be different in less severe cases of pyelonephritis.
Conclusion
Ciprofloxacin and Trimethoproim-sulfamethaxazole should be avoided as first line empiric antibiotics for severe cases of uncomplicated pyelonephritis in this Midwest teaching hospital.
